Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some...

Descripción completa

Detalles Bibliográficos
Autores principales: Nan, Feifei, Fu, Xiaorui, Chen, Xinfeng, Li, Ling, Li, Xin, Wu, Jingjing, Feng, Xiaoyan, Wu, Xiaolong, Yan, Jiaqin, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399606/
https://www.ncbi.nlm.nih.gov/pubmed/36032118
http://dx.doi.org/10.3389/fimmu.2022.929221
Descripción
Sumario:The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.

Ejemplares similares